[{"orgOrder":0,"company":"Advanced Medicine Partners","sponsor":"Deerfield Management","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"JAG201","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Advanced Medicine Partners","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Advanced Medicine Partners \/ Deerfield Management","highestDevelopmentStatusID":"4","companyTruncated":"Advanced Medicine Partners \/ Deerfield Management"}]

Find Clinical Drug Pipeline Developments & Deals by Advanced Medicine Partners

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          CRS
                          Not Confirmed
                          CRS
                          Not Confirmed

                          Details : Proceeds will support CMC efforts for JAG201, a gene therapy in preclinical development for autism spectrum disorder and other neurodevelopmental disorders.

                          Product Name : JAG201

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          January 16, 2024

                          Lead Product(s) : JAG201

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : Deerfield Management

                          Deal Size : Undisclosed

                          Deal Type : Financing

                          blank